STOCKHOLDERS' DEFICIT (Details) - USD ($)
 12 Months Ended
Nov. 09, 2021
Oct. 01, 2021
Sep. 10, 2021
Apr. 01, 2021
Mar. 23, 2021
Feb. 10, 2021
Oct. 01, 2020
May 07, 2018
Aug. 07, 2017
Apr. 21, 2017
Sep. 16, 2016
Oct. 07, 2015
Dec. 31, 2021
Dec. 31, 2020
Nov. 02, 2015
Aug. 04, 2014
Apr. 01, 2013
STOCKHOLDERS' DEFICIT (Details) [Line Items]                                  
Stock Issued During Period, Value, Other                         $ 231,742 $ 51,914      
Gain (Loss) on Extinguishment of Debt   $ 274   $ (1,734)   $ 100,000 $ (984)           (151,410) 182      
Debt Conversion, Original Debt, Amount       9,145               $ 100,000 $ 375,586 $ 0      
Stock Issued During Period, Shares, Issued for Services (in Shares)                         4,000,000 4,000,000      
Stock Issued During Period, Value, Issued for Services                         $ 128,000 $ 16,000      
Debt Conversion, Converted Instrument, Amount   $ 8,921   $ 10,879                          
Debt Conversion, Converted Instrument, Shares Issued (in Shares) 226,713 743,341   187,575 7,518,797   2,035,820         34,522 28,891,144        
Common Stock Registered, Shares (in Shares)     250,000,000                            
Proceeds from Issuance of Common Stock                         $ 275,000 0      
Stock Issued During Period, Shares, New Issues (in Shares)                         27,500,000        
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value                         $ 36,686 296,636      
Share-Based Payment Arrangement, Noncash Expense                         $ 556,556 $ 701,939      
Bioheart 2013 Omnibus Equity Compensation Plan [Member]                                  
STOCKHOLDERS' DEFICIT (Details) [Line Items]                                  
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized (in Shares)                             500,000,000 100,000 50,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized (in Shares)               100,000,000 30,000,000 25,000,000 25,000,000            
Maximum [Member]                                  
STOCKHOLDERS' DEFICIT (Details) [Line Items]                                  
Proceeds from Issuance of Common Stock     $ 2,500,000                            
Interest [Member]                                  
STOCKHOLDERS' DEFICIT (Details) [Line Items]                                  
Stock Issued During Period, Shares, Other (in Shares)                         930,916 3,481,467      
Stock Issued During Period, Value, Other                         $ 19,800 $ 21,744      
Gain (Loss) on Extinguishment of Debt                         1,459 3,404      
Debt Conversion, Original Debt, Amount                         18,340 $ 18,340      
Debt Conversion, Converted Instrument, Amount                         586        
Principal [Member]                                  
STOCKHOLDERS' DEFICIT (Details) [Line Items]                                  
Debt Conversion, Converted Instrument, Amount                         $ 375,000        
Accounts Payable [Member]                                  
STOCKHOLDERS' DEFICIT (Details) [Line Items]                                  
Stock Issued During Period, Shares, Other (in Shares)                         6,642,197 10,354,560      
Stock Issued During Period, Value, Other                         $ 231,742 $ 51,914      
Gain (Loss) on Extinguishment of Debt                         151,742        
Common Stock Issued in Settlement of Accounts Payable, Accrued Expenses and Accrued Interest [Member]                                  
STOCKHOLDERS' DEFICIT (Details) [Line Items]                                  
Gain (Loss) on Extinguishment of Debt                           (3,586)      
Share-Based Payment Arrangement, Option [Member]                                  
STOCKHOLDERS' DEFICIT (Details) [Line Items]                                  
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value                         $ 36,686        
Share Price (in Dollars per share)                         $ 0.006        
Share-Based Payment Arrangement, Noncash Expense                         $ 428,556 $ 685,939      
Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount                         $ 157,289        
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition                         6 months 18 days        
Warrant [Member]                                  
STOCKHOLDERS' DEFICIT (Details) [Line Items]                                  
Share Price (in Dollars per share)                         $ 0.006